Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. The company is headquartered in Boston, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-16. The firm is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Follow-Up Questions
Who is the CEO of Praxis Precision Medicines Inc?
Mr. Marcio Souza is the President of Praxis Precision Medicines Inc, joining the firm since 2020.
What is the price performance of PRAX stock?
The current price of PRAX is $188, it has decreased 1.04% in the last trading day.
What are the primary business themes or industries for Praxis Precision Medicines Inc?
Praxis Precision Medicines Inc belongs to Biotechnology industry and the sector is Health Care
What is Praxis Precision Medicines Inc market cap?
Praxis Precision Medicines Inc's current market cap is $4.2B
Is Praxis Precision Medicines Inc a buy, sell, or hold?
According to wall street analysts, 16 analysts have made analyst ratings for Praxis Precision Medicines Inc, including 6 strong buy, 10 buy, 1 hold, 0 sell, and 6 strong sell
